SPOTLIGHT -
Biologic approved for plaque psoriasis
Scripius Removes Dupixent from Formulary
The decision by Scripius (previously Select Health Prescriptions) was made based on the cost of Dupixent, as well as because of an increased demand to use Dupixent for mild atopic dermatitis when the primary patient population is those with moderate to severe disease.
FDA Approves First Drug for Skin Infection from Pox Virus
Ycanth, a topical treatment for molluscum contagiosum, will be available in September. Pricing information has not yet been released.
FDA Approves Pfizer’s Alopecia Drug
Now with the name Litfulo, ritlecitinib is the first oral treatment for adolescents with alopecia. It has an annual list price of $49,000.
NDA Sets Goal Date for Skin Infection Gel
If approved, berdazimer could be the first prescription product treat molluscum, a common skin infection caused by poxvirus. The Prescription Drug User Fee Act goal date is Jan. 5, 2024.
FDA Expands Cibinqo Label for Atopic Dermatitis in Adolescents
Cibinqo is an oral, once-daily JAK1 inhibitor now approved for those 12 years of age and older.
Express Scripts Adds Zoryve to National Formulary
Launched in August, Zoryve is a once-daily, steroid-free cream and is the first topical PDE4 inhibitor approved to treat plaque psoriasis in patients 12 years of age or older.
